Literature DB >> 8794712

Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes.

R N Frank1, R H Amin, D Eliott, J E Puklin, G W Abrams.   

Abstract

PURPOSE: To determine whether vascular endothelial growth factor and basic fibroblast growth factor, which may be critical mitogens for neovascularization, are present together in human retinal and choroidal neovascular membranes.
METHODS: Light microscopic immunocytochemistry using antibodies against vascular endothelial growth factor, basic fibroblast growth factor, and several cellular "marker" proteins on frozen sections from three choroidal neovascular membranes from patients with age-related macular degeneration, seven surgically excised epiretinal membranes from patients with proliferative diabetic retinopathy, and six epiretinal membranes from patients with nonischemic proliferative retinopathies.
RESULTS: All three choroidal neovascular membranes and all seven epiretinal membranes stained positive for vascular endothelial growth factor. Two choroidal neovascular membranes and six of the epiretinal membranes were positive for basic fibroblast growth factor. The same cells were often positive for both antigens. None of the epiretinal membranes from patients with nonischemic proliferative retinopathies were positive for either growth factor. Many of the cells that demonstrated growth factors were glial cells, vascular endothelial cells, and retinal pigment epithelial cells.
CONCLUSIONS: Colocalization of two growth factors in the same cells of ocular neovascular membranes suggests that more than one growth factor may contribute to pathologic angiogenesis. Growth factors in neovascular tissues are not localized exclusively in the vascular endothelium. Because expression of some growth factors is stimulated by hypoxia, their localization within choroidal neovascular membranes suggests that hypoxia may be an etiologic factor for choroidal as well as for retinal neovascularization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794712     DOI: 10.1016/s0002-9394(14)72066-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  88 in total

1.  Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor.

Authors:  Atsunobu Takeda; Yasuaki Hata; Satomi Shiose; Yukio Sassa; Masae Honda; Kimihiko Fujisawa; Taiji Sakamoto; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-08-23       Impact factor: 3.117

Review 2.  Keypathophysiologic pathways in age-related macular disease.

Authors:  Felix Roth; Almut Bindewald; Frank G Holz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08-10       Impact factor: 3.117

Review 3.  The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity.

Authors:  D Kent
Journal:  Eye (Lond)       Date:  2015-07-31       Impact factor: 3.775

Review 4.  Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration.

Authors:  Goldis Malek; Eleonora M Lad
Journal:  Cell Mol Life Sci       Date:  2014-08-26       Impact factor: 9.261

5.  Expression of hypoxia-inducible factor 1alpha and 2alpha in choroidal neovascular membranes associated with age-related macular degeneration.

Authors:  Yuji Inoue; Yasuo Yanagi; Kyosuke Matsuura; Hidenori Takahashi; Yasuhiro Tamaki; Makoto Araie
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

6.  Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up.

Authors:  Lihteh Wu; J Fernando Arevalo; Mauricio Maia; Maria H Berrocal; Juan Sanchez; Teodoro Evans
Journal:  Jpn J Ophthalmol       Date:  2009-03-31       Impact factor: 2.447

7.  One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups.

Authors:  Seungbum Kang; Young-Jung Roh
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

8.  Human retinal epithelium produces and responds to placenta growth factor.

Authors:  Margrit Hollborn; Solveig Tenckhoff; Marlen Seifert; Stephanie Köhler; Peter Wiedemann; Andreas Bringmann; Leon Kohen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-09       Impact factor: 3.117

9.  Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.

Authors:  Alexander Rouvas; Petros Petrou; Ioannis Vergados; Dimitrios Pechtasides; Vasilios Liarakos; Maria Mitsopoulou; Ioannis Ladas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-16       Impact factor: 3.117

Review 10.  The choroid as a sclera growth regulator.

Authors:  Jody A Summers
Journal:  Exp Eye Res       Date:  2013-03-23       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.